- P. Kahlem
- B. Doerken
- C.A. Schmitt
- Journal of Clinical Investigation
- J Clin Invest 113 (2): 169-174
Damage to DNA, the prime target of anticancer therapy, triggers programmed cellular responses. In addition to apoptosis, therapy-mediated premature senescence has been identified as another drug-responsive program that impacts the outcome of cancer therapy. Here, we discuss whether induction of senescence is a beneficial or, rather, a detrimental consequence of the therapeutic intervention.